期刊
DRUG DEVELOPMENT RESEARCH
卷 80, 期 3, 页码 333-342出版社
WILEY
DOI: 10.1002/ddr.21505
关键词
1,25(OH)(2)D-3; buspirone; CYP3A; testosterone; vitamin D receptor
资金
- National Research Foundation of Korea [2017R1D1A3B03030252, 2016R1D1A1B03931470]
- National Research Foundation of Korea [2017R1D1A3B03030252, 2016R1D1A1B03931470] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
1 alpha,25-Dihydroxyvitamin D-3 (also called 1,25(OH)(2)D-3 or calcitriol) is the biologically active form of vitamin D, which functions as a ligand to the vitamin D receptor (VDR). It was previously reported that intestinal cytochrome P450 3A (CYP3A) expression was altered by 1,25(OH)(2)D-3-mediated VDR activation. However, to clarify whether the change in CYP3A subfamily expression by VDR activation can affect metabolic function, further evidence is needed to prove the effect of 1,25(OH)(2)D-3 treatment on CYP3A-mediated drug metabolism and pharmacokinetics. Here, we report the effects of 1,25(OH)(2)D-3 on CYP3A activity and in vivo pharmacokinetics of buspirone in Sprague-Dawley rats. CYP3A mRNA expression and CYP3A-mediated testosterone metabolism were enhanced in the intestine but were unaffected in the livers of rats treated with 1,25(OH)(2)D-3. Notably, the oral pharmacokinetic profile of buspirone (CYP3A substrate drug) and 6 '-hydroxybuspirone (major active metabolite of buspirone formed via CYP3A-mediated metabolism) was significantly altered, while its intravenous pharmacokinetic profile was not affected by 1,25(OH)(2)D-3 treatment. To the best of our knowledge, this study provides the first reported data regarding the effects of 1,25(OH)(2)D-3 treatment on the in vivo pharmacokinetics of intravenous and oral buspirone in rats, by the differential modulation of hepatic and intestinal CYP3A activity. Our present results could lead to further studies in clinically significant CYP3A-mediated drug-nutrient interactions with 1,25(OH)(2)D-3, including 1,25(OH)(2)D-3-buspirone interaction.Preclinical Research & Development
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据